Gilberto De Lima Lopes, MD

home / authors / gilberto-de-lima-lopes-md

Articles

Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung Cancer

Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung Cancer

Gilberto De Lima Lopes, MD
May 21st 2020

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.

Read More

Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung Cancer

Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung Cancer

Gilberto De Lima Lopes, MD
May 20th 2020

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.

Read More

Dr. Lopes on the FDA Approval of Nivolumab/Ipilimumab in NSCLC

Dr. Lopes on the FDA Approval of Nivolumab/Ipilimumab in NSCLC

Gilberto De Lima Lopes, MD
May 15th 2020

Gilberto De Lima Lopes, MD, discusses the FDA approval of nivolumab (Opdivo) and ipilimumab (Yervoy) in non–small cell lung cancer (NSCLC).

Read More

Dr. Lopes on Standard Durations of Checkpoint Inhibition in Metastatic Lung Cancer

Dr. Lopes on Standard Durations of Checkpoint Inhibition in Metastatic Lung Cancer

Gilberto De Lima Lopes, MD
February 9th 2020

Gilberto De Lima Lopes, MD, discusses the standard of care for pembrolizumab in patients with metastatic lung cancer.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data